Stenotrophomonas maltophilia: Difference between revisions

From IDWiki
Stenotrophomonas maltophilia
()
m ()
Line 1: Line 1:
== Background ==
==Background==


===Microbiology===
===Microbiology===
Line 6: Line 6:
*Multiple mechanisms of resistance
*Multiple mechanisms of resistance
**RND, MfsA, and Sme-related efflux pumps
**RND, MfsA, and Sme-related efflux pumps
**''Sul'' or ''dfrA'' genes (TMP-SMX resistance)
**''Sul'' or ''dfrA'' genes (TMP-SMX resistance)
**β-lactamases
**β-lactamases
**Aminoglycoside-modifying enzymes
**Aminoglycoside-modifying enzymes
Line 20: Line 20:
*Antistenotrophomonal antibiotics:
*Antistenotrophomonal antibiotics:
**[[TMP-SMX]] (preferred agent, if susceptible)
**[[TMP-SMX]] (preferred agent, if susceptible)
**[[Fluoroquinolones]], including [[moxifloxacin]], [[levofloxacin]], and [[ciprofloxacin]] (though develops resistance quickly on monotherapy)
**[[Fluoroquinolones]], including [[moxifloxacin]], [[levofloxacin]], and [[ciprofloxacin]] (though develops resistance quickly on monotherapy)
**[[Minocycline]], [[doxycycline]], and [[tigecycline]]
**[[Minocycline]], [[doxycycline]], and [[tigecycline]]
**[[Ticarcillin-clavulanate]] and [[ampicillin-sulbactam]]
**[[Ticarcillin-clavulanate]] and [[ampicillin-sulbactam]]

Revision as of 01:36, 17 August 2020

Background

Microbiology

  • Aerobic, non-fermentive, catalase-positive, oxidase-negative, Gram-negative bacillus
  • Multiple mechanisms of resistance
    • RND, MfsA, and Sme-related efflux pumps
    • Sul or dfrA genes (TMP-SMX resistance)
    • β-lactamases
    • Aminoglycoside-modifying enzymes

Clinical Manifestations

  • Nosocomial infections with high mortality and high antibiotic resistance

Management